Brief: Adagene Presents Preclinical Data from Lead SAFEbody Program at AACR Annual Meeting 2021
13/04/2021 15:04
April 13 (Reuters) - Adagene Inc ADAG.O :
* ADAGENE PRESENTS PRECLINICAL DATA FROM LEAD SAFEBODY™
PROGRAM,
ADG126, AT THE AMERICAN ASSOCIATION FOR CANCER RESEARCH (AACR)
ANNUAL MEETING 2021
Source text for Eikon: ID:nGNXbpdMlW
Further company coverage: ADAG.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Adagene
See all newsBrief: Adagene To Begin Phase 1 Study Of ADG138 For Advanced Solid Tumors In Q4 2026
Brief: Adagene Announces That Third Arc Bio Has Selected First Lead Candidate Under Amended Strategic Collaboration For Development Of Masked Cd3 T Cell Engagers Utilizing Safebody® Technology
Brief: Adagene Inc Announces Offering Of American Depositary Shares
Brief: Adagene Announces FDA Fast Track Designation For Muzastotug (Adg126)
Brief: Adagene Expands SAFEBody Deal With Exelixis To Develop Third Novel Masked Antibody-Drug Conjugate